Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma
Clinical trial NCT06062485 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06062485
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-01
- Primary completion
- 2025-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.